DCPH / Deciphera Is A Buy In Expectation Of A Significant Comeback

Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sa more_horizontal

Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.60. This more_horizontal

Deciphera Pharmaceuticals is focused on the development of their multikinase inhibitor ripretinib for the treatment of gastrointestinal stromal tumor. more_horizontal

Deciphera Pharmaceuticals' lead therapy is Qinlock, to treat gastrointestinal stromal tumors. Mirati Therapeutics' Krazati is showing promise as a par more_horizontal

Deciphera saw revenue rise by 17.4% year over year. The company's only marketed therapy is Qinlock to treat advanced GIST. more_horizontal

Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales. more_horizontal

After a period of bad news, DCPH has slowly inched back into a positive period. They have a lot of good news and some upcoming catalysts. Current pric more_horizontal

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and c more_horizontal